Lobeglitazone and pioglitazone as add-ons to metformin for patients with type 2 diabetes: a 24-week, multicentre, randomized, double-blind, parallel-group, active-controlled, phase III clinical trial with a 28-week extensionopen access
- Authors
- Jin, S-M; Park, C-Y; Cho, Y. M.; Ku, B. J.; Ahn, C. W.; Cha, B-S; Min, K. W.; Sung, Y. A.; Baik, S. H.; Lee, K. W.; Yoon, K-H; Lee, M-K; Park, S. W.
- Issue Date
- Jun-2015
- Publisher
- WILEY-BLACKWELL
- Keywords
- antidiabetic drug; clinical trial; phase III study; randomised trial; thiazolidinediones
- Citation
- DIABETES OBESITY & METABOLISM, v.17, no.6, pp 599 - 602
- Pages
- 4
- Indexed
- SCIE
SCOPUS
- Journal Title
- DIABETES OBESITY & METABOLISM
- Volume
- 17
- Number
- 6
- Start Page
- 599
- End Page
- 602
- URI
- https://scholarworks.korea.ac.kr/kumedicine/handle/2020.sw.kumedicine/29977
- DOI
- 10.1111/dom.12435
- ISSN
- 1462-8902
1463-1326
- Abstract
- We aimed to compare the efficacy and safety of lobeglitazone and pioglitazone as add-ons to metformin in patients with type 2 diabetes. Patients who were inadequately controlled by metformin were randomized and treated once daily with either lobeglitazone (0.5mg, n= 128) or pioglitazone (15 mg, n= 125) for 24weeks, with a 28-week extension trial of lobeglitazone treatment in patients who consented. The primary endpoint was the change in glycated haemoglobin (HbA1c) concentration from baseline to week 24. At week 24, the mean change from baseline in HbA1c was -0.74% for the lobeglitazone group and -0.74% for the pioglitazone group, with a mean difference of 0.01% [95% confidence interval (CI) of difference, -0.16 to 0.18]. The effects of lobeglitazone on lipid variables and the adverse events associated with lobeglitazone were similar to those observed with pioglitazone. Lobeglitazone was not inferior to pioglitazone as an add-on to metformin in terms of their efficacy and safety.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - 2. Clinical Science > Department of Endocrinology and Metabolism > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.